Clinical trials: Cirrhosis
Hepatitis D, Hepatitis B
Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
Portal hypertension (PH) is one of the key drivers of clinical deteoration in patients with liver cirrhosis. It has been demonstrated that antiviral therapy in patients with chronic hepatitis C infection leads to a decrease of PH…
- Conditions
- Hepatitis D, Hepatitis B, Portal Hypertension, Liver Cirrhosis
- Trial name
- IMPHROVE-D (NCT04863703)
- Testing
- Bulevirtide
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Hannover Medical School
Liver Fibrosis, Pediatric Disorder
Pediatric Liver Transplantation-Liver Fibrosis Evaluation by Using Fibrosis Panel
Liver transplantation in children is highly successful with >80% having 20 years survival. Most pediatric liver diseases are potentially curable with liver transplantation and it is important to establish whether children who…
- Conditions
- Liver Fibrosis, Pediatric Disorder, Liver Transplant; Complications
- Trial name
- PT-LiFE (NCT05308628)
- Testing
- Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA etc.)
- Where
- 2 sites in China
- Volunteers
- 1,200 people
- Sponsor
- RenJi Hospital
Alzheimer Disease, Late Onset, Stroke
Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care
Since September 1st, 2009, Taiwan has begun to pay attention to the care of patients with organ failure, dementia and the elderly, and brought eight of non-cancer terminal patients into health insurance subsidies to implement the…
- Conditions
- Alzheimer Disease, Late Onset, Stroke, Heart Failure, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT05407272
- Testing
- Health Education Manual, manual
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wen-Shiou Pan
Liver Cirrhosis, Gastrointestinal Bleeding
Utilizing of Physiological Parameters Predict the Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding
Can physiological indicators such as quick Sequential Organ Failure Assessment , Shock Index, and its derived indicators such as Modified Shock Index , Age Shock Index and Respiratory Adjusted Shock Index accurately predict the…
- Trial name
- SI (NCT06680583)
- Testing
- physical indicators such as shock index relatives
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- St. Martin De Porress Hospital
Chronic Hepatitis C, Fibrosis
Combination Drug Therapy for Patients With Hepatitis C
Hepatitis C is a major cause of liver disease in the United States and leads to cirrhosis of the liver in approximately one-third of patients some of whom will ultimately suffer from liver failure or liver cancer.
- Conditions
- Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
- Trial name
- NCT00001729
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Anorexia Nervosa
Liver Biomarkers in Anorexia Nervosa
The main goal of the Liver Biomarkers in Anorexia Nervosa (LIBAN) study is to determine the prevalence of liver fibrosis in patient with Anorexia Nervosa.
- Trial name
- LIBAN (NCT05861375)
- Testing
- Fibroscan
- Where
- France
- Volunteers
- 43 people
- Sponsor
- Nantes University Hospital
Portal Hypertension, Cirrhosis
Esophageal Capsule Endoscopy in Children
The portal hypertension (PHT) is the main complication in patients presenting with cirrhosis. It can be the direct cause of bleeding by rupture of the esophageal or gastric varices and can also contribute to the development of…
- Trial name
- PREVOCAP (NCT01551966)
- Testing
- Wireless esophageal capsule endoscopy ( PillCam Eso2)
- Where
- 7 sites in France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Hepatitis B Virus, Decompensated Cirrhosis
Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis
The aim of this study is to evaluate the effect of Entecavir for patients With decompensated HBV-Related cirrhosis.
- Trial name
- NCT00663182
- Testing
- Entecavir
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Changzheng Hospital
Liver Cirrhosis, Portal Vein
Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis
The prevalence of portal vein thrombosis (PVT) in patients with liver cirrhosis is 5-20%. Current evidence regarding the effect of portal vein thrombosis on the prognosis of cirrhotic patients remains under debate.
- Conditions
- Liver Cirrhosis, Portal Vein, Venous Thrombosis, Varicose Veins
- Trial name
- NCT02335580
- Testing
- Somatostatin and its analogs, Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection
- Where
- China
- Volunteers
- 475 people
- Sponsor
- General Hospital of Shenyang Military Region
Hepatitis C Virus Infection
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 …
- Trial name
- MAGELLAN-3 (NCT02939989)
- Testing
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 33 people
- Sponsor
- AbbVie
Pediatric Non-alcoholic Fatty Liver Disease
Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic.
- Trial name
- NCT05309863
- Testing
- Lifestyle management
- Where
- 3 sites in Belgium
- Volunteers
- 850 people
- Sponsor
- University Hospital, Ghent
NAFLD/MAFLD, Liver Fibrosis
Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.
Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.
- Conditions
- NAFLD/MAFLD, Liver Fibrosis, CMR
- Trial name
- NCT05239260
- Testing
- CMR
- Where
- Austria
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Decompensated Cirrhosis
Incidence & Predictive Factors of Recompensation in Children With Decompensated Cirrhosis as Per the Baveno VII Criteria
Cirrhosis is a leading cause of morbidity and mortality world- wide and can develop on the basis of repetitive and/or chronic liver injury due to toxic, infectious, metabolic and genetic pathogenic factors.
- Trial name
- NCT06344611
- Testing
- Other
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Diseases
Role of Combined Ultrasound Elastography in Evaluation the Degree of Liver Fibrosis in Children With Cholesteric Liver Disease
Pediatric CLDs are diverse, encompassing a broad spectrum of conditions, from congenital and metabolic disorders to autoimmune and viral diseases.
- Trial name
- NCT06724731
- Volunteers
- 45 people
- Sponsor
- Assiut University
Portal Hypertension
Correlation of Platelets Count With Endoscopic Findings in a Cohort of Egyptian Patients With Liver Cirrhosis
Portal hypertension is a common complication of liver cirrhosis that can lead to development of esophageal varices (EV). They are abnormally dilated veins within the wall of the esophagus that lead to haemorrhage (1).
- Trial name
- NCT02621372
- Testing
- platelet count
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sherief Abd-Elsalam
Liver Fibrosis
Development of Predictive Indicators of Homogeneous Propagation of Ultrasound and Elastic Waves During VCTE Examination
This is an European, prospective, interventional, and multicenter exploratory clinical investigation that will take place in 6 French sites and 200 patients will be included (adults and children).
- Trial name
- NCT04747457
- Testing
- Research FibroScan
- Where
- 6 sites in France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Echosens
Elastography, Fibrosis, Liver
The Use of the Transient Elastography Paediatric Probe, Compared to the M Probe, Indirect Biomarkers and Histology
The purpose of this study is to assess the reliability, reproducibility and accuracy of the paediatric probe of transient elastography in detecting liver fibrosis in children, besides its limitations and side effects.
- Conditions
- Elastography, Fibrosis, Liver, Pediatrics, Chronic Liver Disease
- Trial name
- NCT04380493
- Testing
- hepatic transient elastography using S probe and M probe
- Where
- Spain
- Volunteers
- 141 people
- Sponsor
- Hospital Vall d'Hebron
Cirrhosis of Liver Due to Hepatitis B (Disorder)
Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients
The study aims to demonstrate that whether treatment of nucleoside （acid）analogues (NAs) plus pegylated interferon (Peg IFN) α-2b for those NAs treated, low level of HBsAg, hepatitis B related compensatory cirrhosis patients will…
- Trial name
- NCT03969017
- Testing
- pegylated interferon (Peg IFN)α-2b, Nucleoside （acid）analogue (NAs)
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Lysosomal Acid Lipase Deficiency, Wolman Disease
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency.
- Trial name
- NCT01371825
- Testing
- Sebelipase alfa (SBC-102)
- Where
- 7 sites in United States, Egypt and 3 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Liver Cirrhosis
Sleep Timing and Circadian Preferences in A Sample of Egyptian Patients With Hepatic Cirrhosis
Individuals with hepatic cirrhosis (n=50) and healthy controls (n=30) were recruited. Sleep quality, sleep timing parameters and circadian preference were evaluated using the Pittsburgh Sleep Quality Index (PSQI), Sleep Timing…
- Trial name
- NCT02710227
- Testing
- (PSQI), (STQ).
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sherief Abd-Elsalam